Merck (MRK) Cash from Operations (2009 - 2026)

Merck (MRK) posted quarterly Cash from Operations of 3918000000.0 for Q1 2026, up 56.72% YoY from 2500000000.0 in Q1 2025, and up 37.14% sequentially from 2857000000.0 in Q4 2025.

Merck (MRK) Cash from Operations (2009 - 2026) Analysis & Trends

Merck has disclosed Cash from Operations across 18 years of filings, most recently posting 3918000000.0 for Q1 2026.

  • In Q1 2026, Cash from Operations rose 56.72% year-over-year to 3918000000.0; the TTM figure through Mar 2026 stood at 17890000000.0 (down 14.31% YoY), while the FY2025 annual figure was 16472000000.0, down 23.27% from the prior year.
  • Cash from Operations grew to 3918000000.0 in Q1 2026, from 2857000000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for MRK reached as high as 9291000000.0 in Q3 2024 and fell as low as 246000000.0 in Q4 2023.
  • The 5-year median for Cash from Operations is 3918000000.0 (2026), against an average of 4350529411.76.
  • Annual changes were most pronounced in 2023 — Cash from Operations plunged 94.45% — and 2024, when it surged 1302.44%.
  • A 5-year view of Cash from Operations shows it stood at 4430000000.0 in 2022, then sank by 94.45% to 246000000.0 in 2023, then surged by 1302.44% to 3450000000.0 in 2024, then retreated by 17.19% to 2857000000.0 in 2025, then soared by 37.14% to 3918000000.0 in 2026.
  • According to Business Quant data, Cash from Operations over the past three periods registered 3918000000.0, 2857000000.0, and 7822000000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 5.33 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 2.51 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 3.83 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn -
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn 3.92 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 2.19 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 2.54 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 2.62 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn 645.50 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 3.92 Bn
Mar 31, 2026 3.92 Bn
Dec 31, 2025 2.86 Bn
Dec 31, 2025 2.86 Bn
Sep 30, 2025 7.82 Bn
Sep 30, 2025 7.82 Bn
Jun 30, 2025 3.29 Bn
Jun 30, 2025 3.29 Bn
Mar 31, 2025 2.50 Bn
Mar 31, 2025 2.50 Bn
Dec 31, 2024 3.45 Bn
Dec 31, 2024 3.45 Bn
Sep 30, 2024 9.29 Bn
Sep 30, 2024 9.29 Bn
Jun 30, 2024 5.64 Bn
Jun 30, 2024 5.64 Bn
Mar 31, 2024 3.09 Bn
Mar 31, 2024 3.09 Bn
Dec 31, 2023 246.00 Mn
Dec 31, 2023 246.00 Mn